Update
$Centessa Pharmaceuticals (CNTA.US)$ BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
Part 5 data from the Phase 2a study (AP-0101) showed a continued favorable safety and tolerability profile for SerpinPC, as well as sustained long-term efficacy results, as measured by a 96% reduction in the median all-bleed annualized bleeding rate (ABR) from the prospective baseline. Consistent with data from earlier portions of the Phase 2a study, there were no thromboembolic events and no treatment-related sustained elevations of D-dimer observed throughout Part 5. D-dimer is a sensitive measure of excess thrombin generation. In addition, there were no SerpinPC-related adverse events observed during Part 5.![]()
Part 5 data from the Phase 2a study (AP-0101) showed a continued favorable safety and tolerability profile for SerpinPC, as well as sustained long-term efficacy results, as measured by a 96% reduction in the median all-bleed annualized bleeding rate (ABR) from the prospective baseline. Consistent with data from earlier portions of the Phase 2a study, there were no thromboembolic events and no treatment-related sustained elevations of D-dimer observed throughout Part 5. D-dimer is a sensitive measure of excess thrombin generation. In addition, there were no SerpinPC-related adverse events observed during Part 5.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment